Market Research Report
Stem Cell Therapy Market Size By Type, By Therapeutic Area, End-use, COVID-19 Impact Analysis, Regional Outlook, Technology Potential, Competitive Market Share & Forecast, 2021 - 2027
|Stem Cell Therapy Market Size By Type, By Therapeutic Area, End-use, COVID-19 Impact Analysis, Regional Outlook, Technology Potential, Competitive Market Share & Forecast, 2021 - 2027|
Published: December 17, 2021
Global Market Insights Inc.
Content info: 110 Pages
Delivery time: 2-3 business days
The stem cell therapy market is anticipated to expand substantially by 2027 on account of ongoing R&D in the field and recent advancements in regenerative medicines across key regions.
Stem cells possess the ability to differentiate into a variety of different cell types. The key characteristics of stem cells include their ability to develop into a specific adult cell type and constant self-renewal. Stem cells are extensively used in tissue repair and regeneration owing to their ability to build every tissue in the human body.
Growing awareness and capabilities of healthcare institutions across developing economies, particularly regarding the benefits of stem cell therapy has fueled market expansion in recent years.
Several industry players have been engaging in profitable strategies to tap into emerging trends in the market, which has favorably impacted the overall business landscape. For instance, in July 2021, Astellas Pharma Inc., a global pharmaceutical company, announced a collaboration with Minovia Therapeutics, Ltd., a leading biotechnology company.
According to the terms of the deal, both firms have agreed to combine expertise to conduct R&D as well as the commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
In another instance, in May 2021, FUJIFILM Cellular Dynamics, Inc., a prominent manufacturer of human cells for regenerative medicine applications, entered into an alliance with BlueRock Therapeutics LLC, a major biopharmaceutical company, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics and co-founder David Gamm. The alliance is intended to enable collaborative R&D efforts towards the development of cell therapies for eye diseases.
The stem cell therapy market has been categorized on the basis of type, end-use, therapeutic area, and regions. With respect to type, the market has further been divided into autologous and allogenic. The autologous sub-segment is expected to attain a valuation of around USD 11.0 billion by the end of 2027.
In terms of therapeutic area, the stem cell therapy market has been segmented into neurology, oncology, cardiovascular, orthopedic, and others. In 2020, the orthopedic sub-segment accounted for revenues worth nearly USD 850.5 million and is set to grow at a sturdy pace over the assessment period.
From the end-use perspective, the market has been bifurcated into clinics, hospitals, and others. The stem cell therapy market from the clinics sub-segment is speculated to amass significant gains by 2027, expanding at a pace of approximately 10.8% CAGR through the analysis timeline.
On the regional front, the Latin America stem cell therapy market held a market share of almost 7.4% in 2020 and is likely to showcase optimistic growth over the forecast timeframe.
The Middle East & Africa stem cell therapy market is poised to gain notable traction by 2027, growing at an impressive CAGR of over 10.5% through the study timeline.